Navigation Links
Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
Date:3/10/2008

- Formulation Has Potential to Address Large Acute Pain Prescription Drug

Market -

LAVAL, QC, March 10 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has begun enrolling patients in its Phase III clinical trial for its twice-daily, tramadol-acetaminophen combination product (study 06CCL3-001).

"Tramadol-acetaminophen combination products have become widely prescribed based on their ability to provide the analgesic potency of tramadol and the rapid efficacy of acetaminophen, as well as their use in treating a broad spectrum of pain types," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "Our formulation has the potential to be the first twice-daily tramadol-acetaminophen product, as well as to compete in the broader acute pain prescription drug market globally. Accordingly, it would be an excellent complement to our once-daily tramadol product for the treatment of persistent pain."

Currently marketed tramadol-acetaminophen combination products must be administered four- to six-times per day. Labopharm believes that by metering the release of both tramadol and acetaminophen from a single tablet using its Contramid(R) controlled-release technology, its formulation has the potential to offer enhanced patient compliance through twice-daily administration, as well as a potentially improved side effect profile. More importantly, based on its potential potency, efficacy, safety and convenience, the Company's novel formulation of tramadol-acetaminophen could be well positioned as an alternative to other prescription products for the treatment of mild to moderate acute pain, including mild-opioids, tramadol, COX-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs) and combination forms of these products.

Study 06CCL3-001 is a multi-centre, randomized, double-blind, parallel-arm study that will compare the efficacy and safety o
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of ... Appalachian Trail by stepping off Springer Mountain and heading north. Since that day, Phil ... reached Connecticut and was greeted by friends and family. He visited CCAR and left ...
(Date:7/31/2015)... ... , ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA ... the Super Bowl. In the two weeks that separate the conference championships and the Super ... Super Bowl game will mark the 50th time it has been held and the festivities ...
(Date:7/31/2015)... Tenn. (PRWEB) , ... July 31, 2015 , ... The ... Robert Church Park in Downtown Memphis on October 3, 2015. The Ride to Fight ... focused on cancer research between Methodist Healthcare, The West Clinic and The University of ...
(Date:7/31/2015)... ... ... Coco Libre announced today that their flagship Organic Coconut Water will be ... Open of Surfing, July 25 through August 2 in Huntington Beach, California. Coco Libre, ... is a natural choice given the Open’s commitment to sustainable practices. , Designated ...
(Date:7/31/2015)... ... ... Well-known for its unique pastries and delicious confections, Pastry Palace, a popular ... life just a little bit sweeter for newlyweds. A family-owned business, the Pastry Palace ... , The bakery provides a full line of custom wedding cakes. Brides can select ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... (NYSE: TYC , BSX: TYC) announced today that ... quarterly dividend to 15,cents per share for the first ... 36% increase over the quarterly dividend of,approximately 11 cents ... the separation of Tyco into three public companies. The,15-cent ...
... ViroPharma Incorporated,(Nasdaq: VPHM ) today announced ... financial officer of ViroPharma, will present,at the Maxim ... ET on,Thursday, September 20, 2007. The conference is ... ViroPharma,s presentation will be webcast live for ...
... straight men equally prone to unprotected sex, research shows , , ... gay men can,t be explained by their number of sexual ... HIV infections diagnosed in the United States in 2005 were ... Seattle, noted. In addition, as many as one in five ...
... Institute have shown that several, rather than just ... brain tumors and other solid tumors, explaining why ... often yields disappointing results. , The laboratory finding ... combine three or more such targeted drugs for ...
... Sept. 13 Mayo Clinic,s,Multidisciplinary Simulation Center is ... the United States to be accredited by,the American ... positions,Mayo to offer and advance medical education that ... members, abilities to keep pace with,rapidly changing technologies. ...
... Minnesota Twins and at Interlachen Country Club ... and support for suicide prevention., MINNEAPOLIS, Sept. 13 ... Prevention Week,(September 9-15, 2007) this week with a special ... at the Hubert H. Humphrey Metrodome in,Minneapolis. SAVE is ...
Cached Medicine News:Health News:Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program 2Health News:Number of Partners Doesn't Explain Gay HIV Rate 2Health News:Number of Partners Doesn't Explain Gay HIV Rate 3Health News:Study suggests brain tumors need treatment with multiple 'targeted' drugs 2Health News:Study suggests brain tumors need treatment with multiple 'targeted' drugs 3Health News:Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute 2Health News:Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute 3Health News:SAVE Recognizes National Suicide Prevention Week 2
(Date:7/31/2015)... Pa. , July 31, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... the closing of its previously announced underwritten public ... at a public offering price of $11.25 per ... offering included 1,000,000 shares issued upon the exercise ...
(Date:7/31/2015)... According to a new market ... Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air ... & Forecast to 2019", published by MarketsandMarkets, the global ... 2014 and is estimated to grow to $1,425.7 Million ... 2014 to 2019. Browse 41 market ...
(Date:7/30/2015)... July 30, 2015  ResMed (NYSE: ... a definitive agreement to acquire Curative Medical, ... and sleep-disordered breathing medical devices and accessories. ... in China, combined with ResMed,s global leadership in sleep and respiratory ... China suffering from sleep-disordered ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Cardiothoracic Surgeons to Lead Pivotal TrialANN ARBOR, Mich., March ... has appointed David Seth Feldman, MD/PhD, FACC, FAHA to ... the United States, studying the new, third generation DuraHeart(TM) ... Dr. Francis Pagani, Director of the Heart Transplant and ...
... - Conference Call Today at 5:00 p.m. Eastern Time ... Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... the fourth quarter and year ended December 31, 2008, ... of 2008, we made significant progress toward our goal ...
Cached Medicine Technology:David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 2David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 3Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 8Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 9
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: